The aim of this study was to compare peloid therapy in addition to home exercise with home exercise alone in terms of pain, function, quality of life, and depression in patients with chronic low back pain (cLBP). A total of 106 cLBP patients were divided into two equal groups as treatment and control. The peloid therapy group had peloid therapy (with a total of 15 sessions on 5 days per week for 3 weeks duration with 45 °C temperature lasting 30 min/day) + home exercise program. The control group was only given a home exercise program. Patients completed the visual analog scale-pain (VAS-pain), patient and physician global assessments (VAS-PGA and VAS-PhGA), revised Oswestry disability index (rODI) for functional status, the short form-36 (SF-36) for quality of life, and Beck Depression Inventory (BDI) for depression three times as before treatment, after treatment (3rd week), and 1 month after the end of treatment. Assessments in the 3rd week at the end of treatment revealed statistically significant improvements for rODI (p = 0.013), VAS-pain (p = 0.039), and VAS-PhGA (p = 0.002) parameters in the peloid therapy group compared to the control group. Assessments in the 1st month after the end of treatment revealed statistically significant improvements in rODI (p < 0.001), VAS-pain (p < 0.001), VAS-PGA (p = 0.002), VAS-PhGA (p < 0.001), and SF-36VE (p = 0.022) parameters in the peloid therapy group compared to the control group. Peloid therapy + home exercise was statistically significantly superior to home exercise alone in improving pain and function in patients with cLBP. Peloid therapy may be recommended as a non-pharmacological treatment for cLBP patients. There is a need for randomized studies with longer follow-up including biochemical parameters to verify the beneficial effects observed in this study and elaborate the mechanisms of action.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00484-021-02137-6 | DOI Listing |
Transplant Cell Ther
January 2025
Dana-Farber Cancer Institute, Division of Transplantation and Cellular Therapy, Boston, MA. Electronic address:
Background: Post-transplant cyclophosphamide (PTCy) is a commonly used graft-vs-host disease (GVHD) prophylaxis, particularly in the setting of haploidentical (haplo) hematopoietic cell transplantation (HCT). The rate of graft failure has been reported to be as high as 12-20% in haplo-HCT recipients using PTCy. The objective of this study was to determine if donor type influenced the risk of late graft failure following RIC HCT using PTCy-based GVHD prophylaxis.
View Article and Find Full Text PDFRheumatol Int
December 2024
Chair of Psychiatry and Narcology, Astana Medical University, Astana, Kazakhstan.
Chronic pain and restricted mobility, hallmark features of rheumatic diseases, substantially affect patients' quality of life, often resulting in physical disability and emotional distress. Given the long-term nature of these conditions, there is a growing interest in complementary therapeutic approaches, emphasizing the need to explore non-pharmacological treatments. Hydrotherapy, balneotherapy, and mud therapy have emerged as effective interventions to alleviate pain, reduce inflammation, improve joint mobility, and enhance overall physical and mental well-being.
View Article and Find Full Text PDFScand J Med Sci Sports
December 2024
School of Psychology, Shanghai University of Sport, Shanghai, China.
Acute high-intensity interval training (HIIT) has cognitive benefits in individuals with methamphetamine use disorder (MUD), yet it remains largely unknown the benefits of long-term HIIT on emotional conflict control and its neural mechanism in individuals with MUD. The current study conducted a 36-week low-volume HIIT intervention to investigate the effects of HIIT on emotional conflict control in males with MUD and their prefrontal cortex (PFC) activation. This study was a sub-study of the Study for Rehabilitation Training Model Construction and Training Effect of High Intensity Compound Exercise Prescription.
View Article and Find Full Text PDFInt J Mol Sci
December 2024
Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Ave., Detroit, MI 48201, USA.
In recent years, methamphetamine (METH) misuse in the US has been rapidly increasing, and there is no FDA-approved pharmacotherapy for METH use disorder (MUD). In addition to being dependent on the drug, people with MUD develop a variety of neurological problems related to the toxicity of this drug. A variety of molecular mechanisms underlying METH neurotoxicity has been identified, including the dysfunction of the neuroprotective protein parkin.
View Article and Find Full Text PDFAnn Hematol
December 2024
Medical Center of Hematology, State Key Laboratory of Trauma and Chemical Poisoning, Xinqiao Hospital, Army Medical University, Chongqing, China.
In recent years, great progress has been made in haploidentical hematopoietic stem cell transplantation (haplo-HSCT) treatment for hematological malignant diseases because of the advent of novel conditioning regimens, optimized graft manipulation, improved graft-versus-host disease (GVHD) prophylaxis, and advances in supportive care. Recent studies have shown very favorable outcomes in severe aplastic anemia (SAA) patients, with comparable outcomes to those of patients receiving immune suppressive therapy (IST) and allogeneic HSCT from a matched sibling donor (MSD) or matched unrelated donor (MUD). However, most of the previous studies relied on single-center data analyses, and the conditioning regimen, GVHD prophylaxis and supportive care used were relatively singular.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!